BIOCYTOGEN PHARMA. H YC1 - Asset Resilience Ratio
BIOCYTOGEN PHARMA. H YC1 (I54) has an Asset Resilience Ratio of 0.35% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2023)
This chart shows how BIOCYTOGEN PHARMA. H YC1's Asset Resilience Ratio has changed over time. See BIOCYTOGEN PHARMA. H YC1 (I54) flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down BIOCYTOGEN PHARMA. H YC1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BIOCYTOGEN PHARMA. H YC1 market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €8.62 Million | 0.35% |
| Total Liquid Assets | €8.62 Million | 0.35% |
Asset Resilience Insights
- Limited Liquidity: BIOCYTOGEN PHARMA. H YC1 maintains only 0.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
BIOCYTOGEN PHARMA. H YC1 Industry Peers by Asset Resilience Ratio
Compare BIOCYTOGEN PHARMA. H YC1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Jinyu Bio-Technology Co Ltd
SHG:600201 |
Biotechnology | 1.20% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
Annual Asset Resilience Ratio for BIOCYTOGEN PHARMA. H YC1 (2021–2023)
The table below shows the annual Asset Resilience Ratio data for BIOCYTOGEN PHARMA. H YC1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.35% | €8.49 Million ≈ $9.92 Million |
€2.45 Billion ≈ $2.86 Billion |
+0.05pp |
| 2022-12-31 | 0.29% | €8.20 Million ≈ $9.58 Million |
€2.80 Billion ≈ $3.27 Billion |
-4.05pp |
| 2021-12-31 | 4.34% | €100.00 Million ≈ $116.91 Million |
€2.30 Billion ≈ $2.69 Billion |
-- |
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides th… Read more